×
About 298 results

ALLMedicine™ Leukocyte Adhesion Deficiency Center

Research & Reviews  106 results

The Primary Objective of This Study is to Evaluate Efficacy and Safety of AVTX-803 in Patients With Leukocyte Adhesion Deficiency Type II
https://clinicaltrials.gov/ct2/show/NCT05462587

Aug 5th, 2022 - The primary objective of this study is to evaluate the efficacy and safety of AVTX-803 compared to withdrawal in patients with Leukocyte Adhesion Deficiency, Type II (LAD II).

Apheresis of Patients With Immunodeficiency
https://clinicaltrials.gov/ct2/show/NCT01212055

Jul 26th, 2022 - Background Primary immunodeficiency diseases (PID) represent candidate genetic disorders for new therapeutic approaches. Our laboratory is developing new therapies for patients with PID using autologous CD34+ hematopoietic stem cells (HSC). Newer ...

Ustekinumab (Anti-IL-12/23p40 Monoclonal Antibody) in Patients With Leukocyte Adhesion Deficiency Type 1 (LAD1) Who Have Inflammatory Pathology
https://clinicaltrials.gov/ct2/show/NCT03366142

Jul 12th, 2022 - Lymphocyte adhesion deficiency type 1 (LAD1) is an autosomal recessive disorder of leukocyte function. Decreased expression of the <=2 subunit of leukocyte integrins results in abnormal cell-cell and cell extracellular matrix adhesion. This diseas...

Defining the mild variant of leukocyte adhesion deficiency type II (SLC35C1-congenital ...
https://doi.org/10.1002/ajmg.a.62737
American Journal of Medical Genetics. Part A; Tahata S, Raymond K et. al.

Mar 27th, 2022 - Leukocyte adhesion deficiency type II (LAD II, also known as SLC35C1-congenital disorder of glycosylation) is an autosomal recessive disorder characterized by growth and cognitive impairment, peripheral neutrophilia, recurrent infections, and the ...

Premature Loss of Deciduous Teeth as a Symptom of Systemic Disease: A Narrative Literat...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8953685
International Journal of Environmental Research and Publi... Spodzieja K, Olczak-Kowalczyk D

Mar 26th, 2022 - Premature loss of primary teeth can occur as a consequence of dental trauma, neonatal tooth extraction, early childhood caries, or periodontal problems, or it can be a manifestation of systemic disease. This review aims to present systemic disorde...

see more →

Clinicaltrials.gov  12 results

The Primary Objective of This Study is to Evaluate Efficacy and Safety of AVTX-803 in Patients With Leukocyte Adhesion Deficiency Type II
https://clinicaltrials.gov/ct2/show/NCT05462587

Aug 5th, 2022 - The primary objective of this study is to evaluate the efficacy and safety of AVTX-803 compared to withdrawal in patients with Leukocyte Adhesion Deficiency, Type II (LAD II).

Apheresis of Patients With Immunodeficiency
https://clinicaltrials.gov/ct2/show/NCT01212055

Jul 26th, 2022 - Background Primary immunodeficiency diseases (PID) represent candidate genetic disorders for new therapeutic approaches. Our laboratory is developing new therapies for patients with PID using autologous CD34+ hematopoietic stem cells (HSC). Newer ...

Ustekinumab (Anti-IL-12/23p40 Monoclonal Antibody) in Patients With Leukocyte Adhesion Deficiency Type 1 (LAD1) Who Have Inflammatory Pathology
https://clinicaltrials.gov/ct2/show/NCT03366142

Jul 12th, 2022 - Lymphocyte adhesion deficiency type 1 (LAD1) is an autosomal recessive disorder of leukocyte function. Decreased expression of the <=2 subunit of leukocyte integrins results in abnormal cell-cell and cell extracellular matrix adhesion. This diseas...

A Gene Therapy Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-I
https://clinicaltrials.gov/ct2/show/NCT03825783

Dec 7th, 2021 - The study is a pediatric non-randomized open-label Phase I clinical trial. This will include a safety evaluation and preliminary assessment of the efficacy of hematopoietic gene therapy consisting of autologous CD34+ enriched cells transduced with...

A Clinical Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-I
https://clinicaltrials.gov/ct2/show/NCT03812263

Nov 22nd, 2021 - This is a pediatric non-randomized open-label Phase I/II clinical trial. The Phase I portion will include a safety evaluation and preliminary assessment of the efficacy of hematopoietic gene therapy consisting of autologous CD34+ enriched cells tr...

see more →

News  1 results

Deadly Mutation Knocks Out Organ Lining
https://www.medpagetoday.com/genetics/generalgenetics/32255

Apr 19th, 2012 - Action Points Integrin alpha-3 is a transmembrane integrin receptor subunit that mediates signals between the cells and their microenvironment and is involved in regulation of adhesion. This report describes three patients with homozygous mutation...

see more →